The use of p53 to construct tumor vaccines has been extensively studied, and several studies to date have shown that p53 vaccines (including p53 synthetic long peptide vaccine, p53MVA vaccine) can induce specific T cell responses by APC treatment, resulting in increased frequency of CD4+ T cells, CD8+ T cells, and decreased Treg levels. The gene discussed is TP53; the disease is neoplasm.